Global myasthenia gravis treatment market is projected to grow at a considerable CAGR of around 7% during the forecast period (2020-2026). Increasing awareness related to the rare diseases, approval of promising drugs, the emergence of biologics along with the high adoption of immunotherapies is the key factor contributing towards the growth of the myasthenia gravis (MG) treatment market across the globe. Myasthenia gravis is a chronic autoimmune, neuromuscular disorder that leads to weakness in the skeletal muscles. Eyes, face, and swallowing are the most affected muscles. 

In May 2019, the American Academy of Neurology had approved Eculizumab (Soliris), a particularly high-cost biologic that treats rare and ultra-rare diseases to make treatment of myasthenia gravis patients. Therefore, the emergence of new biologics is expected to drive the growth of the global myasthenia market. Ongoing R&D by government or non-government institutions to find new ways to treat autoimmune disorders is anticipated to offer considerable opportunities to the growth of the global market. However, the high cost of treatment is anticipated to hinder the growth of the myasthenia gravis treatment market across the globe.  

Segmental Outlook  

The myasthenia gravis treatment market is segmented on the basis of treatment and end-user. Based on the treatment, the myasthenia gravis treatment market is segmented into medication, surgery, and others. Based on end-user, the market is segmented into hospitals, clinics, and others. Hospitals to hold major market share based on end-user. The presence of a large patient pool and the availability of advanced equipment in hospital settings is anticipated to contribute towards the high share of this market segment. The high number of patients visit and availability of all the treatment options at a single place is another factor contributing to the high share of the market segment.

Medication to be considerable segment based on Treatment 

The high intake of drugs to manage the associated symptoms of the myasthenia gravis is a key factor contributing to the high market share of this market segment. Immunosuppressive drugs such as tacrolimus and cyclosporine and immunotherapies such as eculizumab and corticosteroids are the major medications taken by the myasthenia gravis patients. The presence of a robust product pipeline of drugs used in the treatment of myasthenia gravis is anticipated to drive the growth of this market segment. 

Global Myasthenia Gravis Treatment Market Share by Treatment, 2019 (%)

Regional Outlook 

The global myasthenia gravis treatment market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a considerable market share during the forecast period. High healthcare spending, presence of cohesive government policies for R&D related to the myasthenia gravis treatment along with the presence of huge patient pool are anticipated to be the key factors contributing towards the high share of the North America region. According to the National Organization for Rare Disorders (NORD), in the US around 14-40 per 100,000 individuals suffer from myasthenia gravis on an annual basis. Europe is another region holding a considerable position in the global myasthenia gravis treatment market. The availability of huge funding for the research related to the treatment of neuromuscular and autoimmune disorders is anticipated to make a huge contribution towards the high share of the market in the region.

Global Myasthenia Gravis Treatment Market Growth, by Region 2020-2026

Asia-Pacific to exhibit considerable growth during the forecast period 2020-2026

The rapidly evolving healthcare infrastructure, growing per capita healthcare expenditure, along with the presence of huge targeted patient pool is anticipated to be the key factors driving the growth of the myasthenia gravis treatment market in the Asia-Pacific region. The growing awareness among the population of the emerging economies of the region related to autoimmune disorders such as myasthenia gravis and multiple sclerosis is anticipated to further drive the growth of the market in the region. 

Market Players Outlook

LEO Pharma A/S, Mylan N.V., Bausch Health Companies Inc., Bayer HealthCare AG, Encore Dermatology, Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, Nestle SA, Novartis International AG, Pfizer Inc., and so on are the key companies operating in the myasthenia gravis treatment market across the globe. The major players in the market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the market.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global myasthenia gravis treatment market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.